Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.
Niki GavrielatouYuting LiuIoannis A VathiotisJon ZugazagoitiaThazin Nwe AungSaba ShafiAileen FernandezKurt SchalperAmanda PsyrriDavid L RimmPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
On the basis of our findings, co-location score shows promise as a biomarker associated with outcome after immunotherapy. With further validation, it could have value as a predictive biomarker for the selection of patients with NSCLC receiving treatment with immune checkpoint inhibitors.